Recurrent Glioblastoma clinical trials

Explore recruiting recurrent glioblastoma clinical trials.

Recruiting recurrent glioblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Glioblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Individualized Systems Medicine strategy to target cancer stem cells in patients with recurrent Glioblastoma (ISM-GBM)

Norway

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma

Netherlands, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

Norway

Human Pharmacology (Phase I)- Other EU CTIS Study details

Recurrent Glioblastoma trials by city

Recurrent Glioblastoma in Toronto Recurrent Glioblastoma in Vancouver Recurrent Glioblastoma in Montreal Recurrent Glioblastoma in Calgary Recurrent Glioblastoma in Edmonton Recurrent Glioblastoma in Ottawa Recurrent Glioblastoma in Winnipeg Recurrent Glioblastoma in Quebec City Recurrent Glioblastoma in Hamilton Recurrent Glioblastoma in Kitchener Recurrent Glioblastoma in London Recurrent Glioblastoma in Halifax Recurrent Glioblastoma in New York Recurrent Glioblastoma in Los Angeles Recurrent Glioblastoma in Chicago Recurrent Glioblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease